Solvias opens center for biologics, cell & gene therapy in North Carolina

Monday, January 27, 2025 @ 1:04 pm

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today the opening of its cutting-edge Center of Excellence for Biologics and Cell and Gene Therapy in the heart of Research Triangle Park (RTP), North Carolina. The new facility expands Solvias’ global network of centers and reinforces its commitment to advancing transformative therapies for cancer and rare diseases.

Spanning 50,000 square feet, the new center is Solvias' flagship North American site for large molecule analytical services designed to accelerate the development and commercialization of innovative biologics. The facility will bring approximately 200 new jobs to the Raleigh-Durham area over the next three years and is being rolled out in two phases:

Phase 1: A 20,000-square-foot space for cGMP release testing—featuring cell-based potency and molecular assays—operational immediately.
Phase 2: An additional 30,000 square feet expected to open in July 2025, offering expanded capabilities for stability testing and advanced biophysical characterization.

Equipped with state-of-the art analytical instrumentation, laboratory automation, and advanced digital management systems, the new center offers comprehensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biologics, from preclinical stages to commercial release.

“This Center of Excellence in RTP is a milestone in Solvias’ global growth journey,” said Archie Cullen, Chief Executive Officer of Solvias. “Combining our team’s expertise with advanced technology, we aim to set a new benchmark for delivering high-quality, reliable analytical support. It’s an honor to partner with our clients in bringing groundbreaking therapies to patients worldwide.”

“We are focused on helping our clients succeed with our analytical expertise. We are hiring the best possible talent to be technical partners for our clients, helping them bring therapies to market faster and more efficiently. With this investment, we are committed to be an integral part of the US biopharma innovation ecosystem.” said Ilya Koltover, Chief Commercial Officer of Solvias.

Solvias’ new center expands its global footprint to six centers of excellence and marks the company’s second site in North America.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Altamira Therapeutics: Collaboration on radiopharmaceutical targeting strategies

Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have option to negotiate licensing and supply agreement
January 22, 2025

LubioScience partners with Cayman Chemical to expand research tools for Swiss scientists

LubioScience GmbH, Switzerland’s largest R&D reagent platform, got into a new partnership with Cayman Chemical, a global leader in biochemicals, assay kits, and lipid research tools. This partnership brings Cayman's innovative products and expert services to the Swiss research community, supporting advancements in cancer, neuroscience, metabolism, drug discovery, and more.
January 22, 2025

Ymmunobio and PSI win Innosuisse grant for treatment and diagnostic of solid tumors with radio pharmaceutical

Ymmunobio and the Paul Scherrer Institute win Innosuisse innovation grant to develop a radio pharmaceutical with YB’s proprietary YB-800
January 20, 2025

abc biopply & Preclina: Collaboration to improve predictiveness of preclinical studies

abc biopply AG, a pioneer innovator of humanized multi-organoid disease models, and Preclina Inc., a preclinical contract research organization specializing in immune related disorders and humanized animal models, have announced a strategic collaboration. The partnership between the two companies will provide customers with end-to-end project planning on humanized preclinical models from early in
January 18, 2025

TransHeps: Increasing success in clinical trials with accurate liver injury diagnosis

TransHeps offers objective, patient-specific iDILI (idiosyncratic drug-induced liver injury) causality assessments using patient blood samples. It can be easily integrated into clinical trial workflows. Their biomarker-driven technology helps pharmaceutical and biotech companies reduce clinical trial risks, avoid delays, and ensure safer drug development.
January 16, 2025